What is clonal hematopoiesis of indeterminate potential (CHIP) and how should it be evaluated and managed?

Clonal Hematopoiesis of Indeterminate Potential (CHIP): Overview and Clinical Management

Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition where somatic mutations in hematopoietic stem cells lead to clonal expansion without overt hematologic malignancy, defined by variant allele frequency (VAF) ≥2% in genes associated with myeloid malignancies 1, 2.

Definition and Epidemiology

CHIP represents the presence of genetically distinct blood cell populations in the absence of morphological evidence of hematological malignancies 1. The prevalence increases dramatically with age, affecting approximately 10% of individuals aged 70-80 years, translating to an estimated 2.75 million affected individuals in Germany alone 3. The condition becomes increasingly common after age 50 2.

Key Genetic Features

The most frequently mutated genes include 1, 2, 3:

• DNMT3A (most common)
• TET2
• ASXL1
• JAK2
• TP53
• SF3B1
• PPM1D
• SRSF2

CHIP variants typically show VAF of 2-10%, reflecting mutation presence in a subpopulation of blood cells 2. For non-canonical CHIP genes, VAF is mostly below 1% 2.

Risk Factors

Multiple factors beyond age increase CHIP prevalence 4:

• Chemotherapy and radiation exposure 1
• Smoking 1, 4
• Inflammatory conditions
• Premature menopause
• HIV infection
• Obesity
• Germline genetic variation

Clinical Significance

Hematologic Transformation Risk

The annual transformation rate to acute myeloid leukemia or myelodysplastic syndrome is 0.5-1% per year, approximately 13-fold higher than the general population incidence 3, 5. Risk is not well-determined except for specific genes: JAK2, MPL, and MYD88 carry higher transformation risk 1. Any VAF >10% on myeloid malignancy-associated genes warrants close follow-up 1.

Cardiovascular Disease Risk

CHIP confers a two-fold increase in cardiovascular risk independent of traditional risk factors 4. The cardiovascular phenotype is broad and includes 6, 4, 7:

• Atherosclerotic cardiovascular disease (ASCVD)
• Myocardial infarction
• Calcific aortic valve stenosis
• Atrial fibrillation
• Heart failure (both ischemic and non-ischemic)
• Stroke
• Venous thromboembolism
• Myocarditis and pericarditis

Gene-Specific Cardiovascular Mechanisms

Different driver genes produce distinct cardiovascular phenotypes 7:

• TET2 loss-of-function: Inflammasome-linked IL-1β/IL-6 signaling, plaque vulnerability, myocardial inflammation
• DNMT3A mutations: Myeloid epigenetic reprogramming with overlapping inflammatory states
• ASXL1 mutations: Myeloid-skewed hematopoiesis, adverse cardiac remodeling, arrhythmia susceptibility
• JAK2 V617F: Particularly thromboinflammatory profile through amplified NET formation

Other Associated Conditions

CHIP is linked to 5:

• Type 2 diabetes mellitus
• Chronic obstructive pulmonary disease
• Osteoporosis
• Gout
• Potential protective effect in Alzheimer's disease

Diagnostic Considerations

When CHIP is Detected Incidentally

CHIP is increasingly detected as an incidental finding during NGS testing for solid tumors, particularly on plasma cell-free DNA sequencing 1. High-risk CHIP can be found in patients with solid tumors, especially on plasma cfDNA sequencing 1.

Distinguishing CHIP from Tumor-Derived Variants

Key features suggesting hematopoietic origin 2:

1. Variants in canonical CHIP genes (DNMT3A, TET2, ASXL1, JAK2, TP53, SF3B1)
2. Low VAF in samples with high ctDNA fractions
3. Patient age >50 years
4. Absence of cancer-specific mutational profile
5. Stability over time without changes in VAF
6. Normal imaging and clinical findings despite variant detection
7. Known hematologic condition present

Clinical Management Recommendations

Initial Evaluation

When CHIP is discovered incidentally in a patient with normal blood count, obtain a complete blood count with differential at 3 months, then annually 3.

Indications for CHIP Testing

Current research-based recommendations for testing include 5:

1. Persistent unexplained cytopenias (≥4 months duration)
2. Prior to adjuvant cytotoxic chemotherapy and/or radiation therapy in cancer patients
3. Screening before autologous hematopoietic stem cell transplantation
4. Before CAR-T cell therapy
5. To distinguish germline mosaic variants from CHIP

Risk Stratification

Progression risk increases with 3, 5:

• Unexplained cytopenia
• Multiple mutations
• VAF >10% 1
• High-risk genes (JAK2, MPL, MYD88) 1

Cardiovascular Risk Management

For patients with CHIP and cardiovascular risk, selective clinical testing is now justified for high-risk individuals to improve cardiovascular risk stratification and inform preventive care 8. By identifying specific mutations and estimating VAF, clinicians can better understand CHIP-related cardiovascular risk and tailor surveillance strategies 8.

Exploratory data suggest IL-1β inhibition may be particularly beneficial in TET2-CHIP carriers, though this remains hypothesis-generating and requires adequately powered, CHIP-stratified outcome trials 7. Current translational work includes CHIP-enriched studies of inflammasome and IL-1-pathway blockade 7.

CHIP Clinic Model

Specialized CHIP clinics are emerging at academic centers to provide multidisciplinary management 9. These clinics focus on:

• Preventive hematology and real-world risk assessment
• Clinical trial enrollment opportunities
• Curated research registries and biorepositories
• Multidisciplinary team involvement (hematology/oncology, cardiology, pathology, genetics) 10

Critical Pitfalls

1. Do not diagnose myelodysplastic syndrome based solely on molecular findings without morphological criteria 3
2. Do not ignore CHIP variants detected on tumor NGS panels—they require hematologic follow-up 1
3. Do not assume all low-VAF variants in cfDNA are tumor-derived; consider CHIP, especially in patients >50 years 2
4. Do not overlook cardiovascular risk assessment in CHIP patients—the two-fold increased risk is independent of traditional risk factors 4